JP2013523180A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523180A5
JP2013523180A5 JP2013505077A JP2013505077A JP2013523180A5 JP 2013523180 A5 JP2013523180 A5 JP 2013523180A5 JP 2013505077 A JP2013505077 A JP 2013505077A JP 2013505077 A JP2013505077 A JP 2013505077A JP 2013523180 A5 JP2013523180 A5 JP 2013523180A5
Authority
JP
Japan
Prior art keywords
sequence
protein
cell
heterologous protein
endogenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013505077A
Other languages
English (en)
Japanese (ja)
Other versions
JP5841996B2 (ja
JP2013523180A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/032216 external-priority patent/WO2011130345A1/en
Publication of JP2013523180A publication Critical patent/JP2013523180A/ja
Publication of JP2013523180A5 publication Critical patent/JP2013523180A5/ja
Application granted granted Critical
Publication of JP5841996B2 publication Critical patent/JP5841996B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013505077A 2010-04-13 2011-04-13 異種タンパク質を発現するための内因性プロモーターの使用 Active JP5841996B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US32371910P 2010-04-13 2010-04-13
US32370210P 2010-04-13 2010-04-13
US32369810P 2010-04-13 2010-04-13
US61/323,702 2010-04-13
US61/323,719 2010-04-13
US61/323,698 2010-04-13
US36701710P 2010-07-23 2010-07-23
US61/367,017 2010-07-23
US39066810P 2010-10-07 2010-10-07
US61/390,668 2010-10-07
US40885610P 2010-11-01 2010-11-01
US61/408,856 2010-11-01
US201161431957P 2011-01-12 2011-01-12
US61/431,957 2011-01-12
PCT/US2011/032216 WO2011130345A1 (en) 2010-04-13 2011-04-13 Use of endogenous promoters to express heterologous proteins

Publications (3)

Publication Number Publication Date
JP2013523180A JP2013523180A (ja) 2013-06-17
JP2013523180A5 true JP2013523180A5 (https=) 2014-05-08
JP5841996B2 JP5841996B2 (ja) 2016-01-13

Family

ID=44799004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013505077A Active JP5841996B2 (ja) 2010-04-13 2011-04-13 異種タンパク質を発現するための内因性プロモーターの使用
JP2013505078A Active JP5841997B2 (ja) 2010-04-13 2011-04-13 内因性にタグ付けされたタンパク質を生成するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013505078A Active JP5841997B2 (ja) 2010-04-13 2011-04-13 内因性にタグ付けされたタンパク質を生成するための方法

Country Status (10)

Country Link
US (5) US20130065310A1 (https=)
EP (2) EP2558574B1 (https=)
JP (2) JP5841996B2 (https=)
KR (2) KR20130054955A (https=)
CN (3) CN102959078B (https=)
BR (1) BR112012026379A2 (https=)
CA (2) CA2795636C (https=)
DK (1) DK2558575T3 (https=)
ES (1) ES2565216T3 (https=)
WO (3) WO2011130343A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9512444B2 (en) 2010-07-23 2016-12-06 Sigma-Aldrich Co. Llc Genome editing using targeting endonucleases and single-stranded nucleic acids
US9012617B2 (en) * 2011-04-11 2015-04-21 The Trustees Of The University Of Pennsylvania Detection reagents for tyrosine kinase activity and methods of use thereof
AU2012347919B2 (en) * 2011-12-05 2017-02-02 Factor Bioscience Inc. Methods and products for transfecting cells
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
CA2868575C (en) 2012-03-27 2022-11-01 The University Of Western Ontario Sh2 domain variants
EP2839013B1 (en) * 2012-04-18 2020-08-26 The Board of Trustees of the Leland Stanford Junior University Non-disruptive gene targeting
AU2013335451C1 (en) 2012-10-23 2024-07-04 Toolgen Incorporated Composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and Cas protein-encoding nucleic acid or Cas protein, and use thereof
RU2662932C2 (ru) 2013-03-14 2018-07-31 Карибо Биосайенсиз, Инк. Композиции и способы с участием нуклеиновых кислот, нацеленных на нуклеиновые кислоты
BR112016019940A2 (pt) 2014-03-21 2017-10-24 Univ Leland Stanford Junior edição de genoma sem nucleases
PT3514172T (pt) * 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP4464338A3 (en) 2014-11-07 2025-02-12 Editas Medicine, Inc. Systems for improving crispr/cas-mediated genome-editing
US11440946B2 (en) 2015-03-13 2022-09-13 University Of Maryland, Baltimore Universal antibody-mediated biosensor
EP3353296B1 (en) 2015-09-24 2020-11-04 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
KR20250141836A (ko) * 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
WO2017109292A1 (en) * 2015-12-23 2017-06-29 Teknologian Tutkimuskeskus Vtt Oy A method for obtaining indicator signals from a cell
US11597924B2 (en) 2016-03-25 2023-03-07 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
US11236313B2 (en) 2016-04-13 2022-02-01 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
CN106800602B (zh) * 2017-01-22 2020-05-01 中国科学院生物物理研究所 一种可视化标记基因组位点的方法
WO2018148603A1 (en) * 2017-02-09 2018-08-16 Allen Institute Genetically-tagged stem cell lines and methods of use
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2019118879A1 (en) * 2017-12-14 2019-06-20 Donald Danforth Plant Science Center Homologous recombination via transcriptional activation
EP3788150A4 (en) * 2018-05-04 2022-01-26 Sigma-Aldrich Co. LLC PRODUCTION OF RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINS
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
EP3902915B1 (en) * 2018-12-30 2023-08-23 F. Hoffmann-La Roche AG Method for the selection of cells based on crispr/cas-controlled integration of a detectable tag to a target protein
EP4031583A4 (en) * 2019-09-16 2023-11-15 Fred Hutchinson Cancer Center CHIMERIC RECEPTOR PROTEINS AND THEIR USES
CN113684228B (zh) * 2021-10-26 2022-03-11 天九再生医学(天津)科技有限公司 利用内参快速准确表征蛋白质相对丰度的方法
CN114703174B (zh) * 2022-04-12 2023-10-24 中国科学院海洋研究所 快速获得基因型和表型突变的CRISPR/Cas9基因敲除方法及应用
CN115948401A (zh) * 2022-12-19 2023-04-11 中国科学技术大学 一种多靶点rna靶向敲低系统及应用
CN120177781B (zh) * 2025-05-22 2025-08-12 南京师范大学 生物传感器及其应用和高通量筛选花姜酮生产菌的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192772B1 (en) * 1988-08-31 2007-03-20 The University Of Florida Research Foundations, Inc. Recombinant cells that highly express chromosomally-integrated heterologous gene
US7090976B2 (en) * 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
US6495664B1 (en) * 1998-07-24 2002-12-17 Aurora Biosciences Corporation Fluorescent protein sensors of post-translational modifications
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6710170B2 (en) * 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US7125660B2 (en) * 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
AU2002327730A1 (en) * 2001-09-26 2003-04-07 University Of North Carolina At Chapel Hill Variants of alpha-fetoprotein coding and expression sequences
AU2004263865B2 (en) * 2003-08-08 2007-05-17 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7402436B2 (en) * 2004-05-03 2008-07-22 City Of Hope Lentiviral vectors for site-specific gene insertion
WO2006017751A2 (en) * 2004-08-02 2006-02-16 Cellumen, Inc. Methods for the detection of molecular interactions within cells
AU2005287278B2 (en) * 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
US20060171929A1 (en) * 2005-01-31 2006-08-03 The University Of Washington Regulation of dendritic cell functions by the DCAL-2 receptor
EP1869206A4 (en) * 2005-03-02 2011-08-10 Einstein Coll Med ENZYME SENSORS WITH ENVIRONMENTAL SENSITIVE OR FLUORESCENT LABELS AND APPLICATIONS THEREOF
WO2006094073A2 (en) * 2005-03-02 2006-09-08 Acadia Pharmaceuticals Inc. Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
US20070155014A1 (en) * 2005-07-20 2007-07-05 Invitrogen Corporation Methods for increasing efficiency of homologous recombination
US20080305519A1 (en) * 2006-02-23 2008-12-11 Qing Lin Biochemical method for specific protein labeling
WO2007139895A2 (en) * 2006-05-24 2007-12-06 Cellumen, Inc. Method for modeling a disease
EP2205752B1 (en) * 2007-10-25 2016-08-10 Sangamo BioSciences, Inc. Methods and compositions for targeted integration
CA2720903C (en) * 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
SG191561A1 (en) * 2008-08-22 2013-07-31 Sangamo Biosciences Inc Methods and compositions for targeted single-stranded cleavage and targeted integration

Similar Documents

Publication Publication Date Title
JP2013523180A5 (https=)
JP2013523181A5 (https=)
WO2018073393A3 (en) Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
AR095660A1 (es) Métodos de fabricación para el control el contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
FI3461261T3 (fi) Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja
BR112013028523A2 (pt) uso de um anticorpo ou uma proteína de fusão ou um fragmento de ligação da mesma e método para a purificação de um anticorpo, uma proteína de fusão ou um fragmento de ligação da mesma de uma mistura fonte
NZ725079A (en) Transgene genetic tags and methods of use
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
NZ706377A (en) Il-6 antagonists and uses thereof
NZ610091A (en) Antibodies
HRP20240997T1 (hr) Varijabilni fragmenti antitijela koji se mogu umetnuti i modificirane α1-α2 domene nkg2d liganada, kao i neprirodni nkg2d ligandi koji se vežu za neprirodne nkg2d receptore
HRP20190881T1 (hr) Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
MX2021015182A (es) Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso.
MY162564A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
CL2009001001A1 (es) Anticuerpo anti-factor d del complemento; polinucleotido codificante; vector que comprende dicho polinucleotido; celula huesped que comprende dicho vector; metodo de fabricacion del anticuerpo; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares.
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
MY188761A (en) Method of reducing serum levels of fc-containing agents using fcrn antagonists
JP2015532644A5 (https=)
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales
AR109533A2 (es) Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.
AR119270A1 (es) MÉTODOS PARA PRODUCIR UN ANTICUERPO ANTI-a4b7